On May 4th The International Waldenstrom's Macroglobulinemia Foundation (IWMF) held another webinar in its 2021 IWMF Global Education series titled Peripheral Neuropathy: No Easy Feat. As the title implies, the…
Recently the Leukemia & Lymphoma Society (LLS), in coordination with the International Waldenstrom's Macroglobulinemia Foundation (IWMF), hosted its Waldenström's Macrogloblinemia (WM) Patient Education Program webinar on April 7th, 2021. Patient…
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) recently hosted a webinar presentation on February 9, 2021. This webinar, titled "Why Clinical Trials Matter and How to Find the Right One for…
According to a story from newswise.com, a team of researchers from the University of New Hampshire may have discovered the next new treatment for a rare form of blood cancer…
In late December 2020, biopharmaceutical company AbbVie announced via press release that the prescribing information for IMBRUVICA (ibrutinib) is now updated to include long-term safety and efficacy data for…
Waldenstrom macroglobulinemia (WM) is incredibly difficult to treat. In addition to having no cures, the condition only has one approved treatment option. However, researchers now believe that combining drugs, specifically…
On October 14th, 2020, the International Waldenström's Macroglobulinemia Foundation (IWMF) hosted a webinar featuring Dr. Irene Ghobrial of the Dana Farber Cancer Institute. The focus of her presentation was on…
September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of Blood Cancer Awareness Month, which…
In a recent webinar hosted by the International Waldenström's Macroglobulinemia Foundation (IWMF) and held on July 22nd, 2020, Dr. Jeffery Matous from the Colorado Blood Cancer Institute gave an in-depth…
According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US Food and Drug Administration (FDA).…
A new study is seeking to understand how the ongoing coronavirus/COVID-19 pandemic is impacting patients with a rare blood cancer called Waldenström's macroglobulinemia (WM). The research is to be conducted…
According to a story from crweworld.com, the biopharmaceutical company BeiGene, Ltd. recently released the results of a phase 3 clinical trial. The goal of this trial was the comparison of…
According to an announcement from the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the organization has recently added a new fact sheet to their website. This fact sheet is focused on the…
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) has recently announced an exciting new partnership that will help facilitate spreading awareness about Waldenstrom's macroglobulinemia (WM), a rare form of blood cancer. This…
Anita Lawson was paying the doctor a visit for her annual checkup in 2003 when she was told something that surprised her: she had anemia. She had some issues with…
From Friday, June 7th to Sunday, June 9th, 2019, I had the privilege of attending the 2019 International Waldenstrom's Macroglobulinemia Foundation Educational Forum. This year, the annual event was held…
On the weekend of June 7th through 9th, I had the privilege of attending the 2019 International Waldenstrom's Macroglobulinemia Foundation's Annual Educational Forum in Philadelphia, Pennsylvania on the behalf of…
The International Waldenstrom's Macroglobulinemia Foundation (IWMF) is a nonprofit organization founded by patients. Their mission? Support patients currently living with Waldenstrom's Macroglobulinemia (WM) while simultaneously supporting the search for a…
Dana-Farber Cancer Institute has just announced research updates on multiple myeloma and waldenstrom macroglobulinemia which indicate significant progress in the search for treatments for these diseases. The Findings 1) There…
According to a story from BioSpace, the biopharmaceutical company AbbVie recently announced that the US Food and Drug Administration (FDA) has approved a new combination treatment for Waldenstrom's macroglobulinemia (WM).…
A patient with Waldenström Macroglobulinemia taking part in a clinical trial of the experimental drug CLR 131 for the treatment of B-cell hematologic cancers is reported to have achieved a…
The US Food and Drug Administration (FDA) is reviewing a supplemental New Drug Application (sNDA) for the drug Imbruvica (ibrutinib) in combination with rituximab (Rituxan) for treating Waldenström macroglobulinemia. The…
There is support out there for people living with and/or affected by Waldenstrom macroglobulinemia (WM). Thankfully, according to Patient Worthy Partner International Waldenstrom’s Macroglobulinemia Foundation (IWMF,) a gap may be bridged…
According to a lovely post on the International Waldenstrom's Macroglobulinemia Foundation website, Julianne married the love of her life at the age of 19; her husband John was 30. In…
What do you do when you are facing the unknown? We all have to at some point. And many of us will face the unknown while sitting in a doctor’s…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
